HK1189246A1 - Methods and compositions for identifying and treating lupus - Google Patents

Methods and compositions for identifying and treating lupus

Info

Publication number
HK1189246A1
HK1189246A1 HK14102346.1A HK14102346A HK1189246A1 HK 1189246 A1 HK1189246 A1 HK 1189246A1 HK 14102346 A HK14102346 A HK 14102346A HK 1189246 A1 HK1189246 A1 HK 1189246A1
Authority
HK
Hong Kong
Prior art keywords
identifying
compositions
methods
treating lupus
lupus
Prior art date
Application number
HK14102346.1A
Other languages
English (en)
Chinese (zh)
Inventor
Timothy W Behrens
Geoffrey Hom
Ward A Ortmann
Robert Royal Graham
Original Assignee
健泰科生物技術公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 健泰科生物技術公司 filed Critical 健泰科生物技術公司
Publication of HK1189246A1 publication Critical patent/HK1189246A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q99/00—Subject matter not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2533/00—Reactions characterised by the enzymatic reaction principle used
    • C12Q2533/10—Reactions characterised by the enzymatic reaction principle used the purpose being to increase the length of an oligonucleotide strand
    • C12Q2533/101—Primer extension
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Business, Economics & Management (AREA)
  • General Business, Economics & Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Theoretical Computer Science (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK14102346.1A 2007-05-21 2014-03-10 Methods and compositions for identifying and treating lupus HK1189246A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93915607P 2007-05-21 2007-05-21
US1328307P 2007-12-12 2007-12-12
PCT/US2008/064430 WO2008144761A2 (en) 2007-05-21 2008-05-21 Methods and compositions for identifying and treating lupus

Publications (1)

Publication Number Publication Date
HK1189246A1 true HK1189246A1 (en) 2014-05-30

Family

ID=40122294

Family Applications (3)

Application Number Title Priority Date Filing Date
HK14102346.1A HK1189246A1 (en) 2007-05-21 2014-03-10 Methods and compositions for identifying and treating lupus
HK15109984.2A HK1209459A1 (en) 2007-05-21 2014-03-10 Methods and compositions for identifying and treating lupus
HK18114216.9A HK1255086A1 (zh) 2007-05-21 2018-11-07 用於鑒定和治療狼瘡的方法和組合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK15109984.2A HK1209459A1 (en) 2007-05-21 2014-03-10 Methods and compositions for identifying and treating lupus
HK18114216.9A HK1255086A1 (zh) 2007-05-21 2018-11-07 用於鑒定和治療狼瘡的方法和組合物

Country Status (14)

Country Link
US (1) US20110046094A1 (xx)
EP (3) EP3318643A3 (xx)
JP (4) JP5728226B2 (xx)
KR (4) KR101651678B1 (xx)
CN (3) CN103298950B (xx)
AU (1) AU2008254582A1 (xx)
BR (1) BRPI0811930B8 (xx)
CA (1) CA2690608C (xx)
ES (1) ES2661249T3 (xx)
HK (3) HK1189246A1 (xx)
IL (1) IL201949A0 (xx)
MX (2) MX343167B (xx)
RU (1) RU2009147281A (xx)
WO (1) WO2008144761A2 (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103298950B (zh) * 2007-05-21 2015-01-21 健泰科生物技术公司 用于鉴定和治疗狼疮的方法和组合物
AU2009296393A1 (en) * 2008-09-26 2010-04-01 Genentech, Inc. Methods for treating, diagnosing, and monitoring lupus
US20100105061A1 (en) * 2008-10-29 2010-04-29 University Of Southern California Autoimmune genes identified in systemic lupus erythematosus (sle)
US20110319288A1 (en) * 2009-03-03 2011-12-29 Merck Serono S.A. Bank1 related snps and sle and/or ms susceptibility
WO2011044205A1 (en) * 2009-10-07 2011-04-14 Genentech, Inc. Methods for treating, diagnosing, and monitoring lupus
RU2015145543A (ru) * 2010-03-01 2019-01-11 Алексион Фармасьютикалз Инк. Способы и композиции для лечения болезни дего
AU2012214417A1 (en) * 2011-02-10 2013-09-05 Genqual Corporation Methods of prognosing and administering treatment for inflammatory disorders
US20130317006A1 (en) 2012-05-24 2013-11-28 Amy Yasko Use of polymorphisms for identifying individuals at risk of developing autism
WO2015081052A1 (en) 2013-11-27 2015-06-04 Yasko Amy Use of polymorphisms for identifying individuals at risk of developing autism
CN108377651A (zh) * 2015-06-24 2018-08-07 牛津生物动力有限公司 染色体互相作用的检测
CN110459312B (zh) * 2018-05-07 2024-01-12 深圳华大生命科学研究院 类风湿性关节炎易感位点及其应用
EP4076671A4 (en) * 2019-12-18 2024-04-17 Childrens Hospital Philadelphia NOVEL PHARMACOPOTENTIAL TARGETS FOR THE TREATMENT OF INFLAMMATORY DISEASES SUCH AS SYSTEMIC LUPUS ERYTHEMATOSOS (SLE) AND METHODS OF DIAGNOSIS AND TREATMENT USING THE SAME
KR20240021336A (ko) 2022-08-09 2024-02-19 심재홍 수액 채취장치의 냉각기 구조

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683203A (en) * 1984-04-14 1987-07-28 Redco N.V. Immobilized enzymes, processes for preparing same, and use thereof
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
DK0710719T3 (da) 1990-01-12 2007-07-09 Amgen Fremont Inc Frembringelse af xenogene antistoffer
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
CA2255774C (en) 1996-05-29 2008-03-18 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
EP0942968B1 (en) 1996-12-03 2008-02-27 Amgen Fremont Inc. Fully human antibodies that bind EGFR
WO2001092579A2 (en) 2000-05-30 2001-12-06 Pe Corporation (Ny) Methods for detecting target nucleic acids using coupled ligation and amplification
US6900016B1 (en) 2000-09-08 2005-05-31 Applera Corporation Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof
US20070037144A1 (en) * 2000-10-20 2007-02-15 Jay Wohlgemuth Leukocyte expression profiling
US7205106B1 (en) 2001-07-20 2007-04-17 Roche Molecular Systems, Inc. Association of polymorphisms in IL4-related genes with autoimmune disease
JP2003061677A (ja) * 2001-08-28 2003-03-04 Olympus Optical Co Ltd 全身性エリテマトーデスの感受性遺伝子およびその使用
US20030119004A1 (en) 2001-12-05 2003-06-26 Wenz H. Michael Methods for quantitating nucleic acids using coupled ligation and amplification
US7022476B2 (en) * 2002-02-26 2006-04-04 New York Society For Ruptured And Crippled Maintaining The Hospital For Special Surgery Human FcγRIIB gene polymorphisms for assessing development of systemic lupus erythematosus and compositions for use thereof
KR20040102024A (ko) * 2002-03-01 2004-12-03 라브겐, 인코퍼레이티드 유전적 장애의 검출 방법
WO2004083403A2 (en) 2003-03-18 2004-09-30 Applera Corporation Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
WO2005086872A2 (en) * 2004-03-10 2005-09-22 Celera, An Applera Corporation Business Ptpn22 polymorphisms in diagnosis and therapy
EP1863927A2 (en) * 2005-03-15 2007-12-12 Ares Trading S.A. Compositions and methods for treating and diagnosing inflammatory disorders
PT2327792E (pt) 2005-08-05 2013-11-21 Genentech Inc Métodos e composições para a detecção de distúrbios autoimunes
US20070269827A1 (en) * 2006-05-18 2007-11-22 Oklahoma Medical Research Foundation Predicting and Diagnosing Patients With Autoimmune Disease
CN103298950B (zh) * 2007-05-21 2015-01-21 健泰科生物技术公司 用于鉴定和治疗狼疮的方法和组合物
AU2009296393A1 (en) * 2008-09-26 2010-04-01 Genentech, Inc. Methods for treating, diagnosing, and monitoring lupus

Also Published As

Publication number Publication date
EP2612924A2 (en) 2013-07-10
KR101729431B1 (ko) 2017-04-21
WO2008144761A2 (en) 2008-11-27
EP2612924B1 (en) 2017-12-20
EP3318643A3 (en) 2018-06-20
CN108753946A (zh) 2018-11-06
HK1209459A1 (en) 2016-04-01
MX2009012531A (es) 2009-12-03
JP6080059B2 (ja) 2017-02-15
CN104593488B (zh) 2018-06-12
KR20190015629A (ko) 2019-02-13
MX343167B (es) 2016-10-26
EP2158335A2 (en) 2010-03-03
JP2015164426A (ja) 2015-09-17
US20110046094A1 (en) 2011-02-24
CN103298950A (zh) 2013-09-11
WO2008144761A3 (en) 2009-07-02
JP2017035088A (ja) 2017-02-16
JP5728226B2 (ja) 2015-06-03
EP2612924A3 (en) 2013-10-23
AU2008254582A1 (en) 2008-11-27
BRPI0811930B1 (pt) 2019-11-05
KR101947093B1 (ko) 2019-02-12
CA2690608C (en) 2020-07-21
HK1255086A1 (zh) 2019-08-02
BRPI0811930A2 (pt) 2014-11-25
CN103298950B (zh) 2015-01-21
BRPI0811930B8 (pt) 2021-05-25
KR20150133861A (ko) 2015-11-30
ES2661249T3 (es) 2018-03-28
IL201949A0 (en) 2010-06-16
MX353428B (es) 2018-01-12
JP2010528590A (ja) 2010-08-26
KR20170042831A (ko) 2017-04-19
JP2018126146A (ja) 2018-08-16
KR101651678B1 (ko) 2016-08-26
EP3318643A2 (en) 2018-05-09
RU2009147281A (ru) 2011-06-27
KR20100021612A (ko) 2010-02-25
CA2690608A1 (en) 2008-11-27
CN104593488A (zh) 2015-05-06

Similar Documents

Publication Publication Date Title
HK1255086A1 (zh) 用於鑒定和治療狼瘡的方法和組合物
HRP20190214T1 (hr) Pripravci i metode za liječenje purpure
IL257418A (en) Methods for treating addiction
IL193014A0 (en) Methods and compositions for treating schizophrenia
PL2137210T3 (pl) Nowy sposób i kompozycje
ZA201001300B (en) Antigen-asjuvant compositions and methods
HUE037628T2 (hu) Készítmények és eljárások kognitív funkció javítására
IL195619A0 (en) Compositions and methods for joininig non-conjoined iumens
EP2125618A4 (en) METHOD AND COMPOSITION FOR REMOVING PARTICLES
EP2282719A4 (en) COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS
IL210097A0 (en) Compositions and methods for treating unfluenza
EP2355660A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
GB0709781D0 (en) Composition and method
IL216146A0 (en) Methods and compositions for treating lupus
GB0724967D0 (en) Composition and method
GB0721291D0 (en) Methods and compositions
HRP20130642T1 (xx) Postupci i sastavi za lijeäśnje raka
IL210840A0 (en) Methods and compositions for treating and preventing autoimmune diseases
IL204945A0 (en) Compositions and methods for inhibiting tumor progression
EP2340254A4 (en) COMPOSITIONS AND METHODS FOR TREATING EPILEPSY
GB0719526D0 (en) Compositions and methods
ZA201004212B (en) Method and composition for treating an alpha adrenoceptor-mediated condition
GB201008346D0 (en) Methods and compounds for phototransfer
EP2170314A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PHENYLCETONURIA
EP2183380A4 (en) METHODS AND COMPOSITIONS FOR PCR